By Benjamin Horney ( August 14, 2014, 6:25 PM EDT) -- The U.S. Securities and Exchange Commission is investigating whether a hostile takeover bid for Allergan Inc. — made by Valeant Pharmaceuticals International Inc. and billionaire activist investor William Ackman — constitutes a violation of securities laws, people familiar with the matter told Dow Jones on Thursday. The bid, which was launched in April with an original price tag of $48 billion and was eventually upped to about $53 billion, prompted Allergan to allege insider trading in a suit lodged earlier this month. The SEC is looking into the insider trading allegations and is still at a "relatively early stage," according to the Dow Jones report....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.